Respiratory Disorders Market to Reach USD 213.12 Billion by 2033 | CAGR 6.6% | North America Leads with 35% Share | Key Players: GSK, AstraZeneca, Boehringer Ingelheim, Sanofi, Regeneron, Novartis, Merck, Pfizer, Teva, Roche

Respiratory Disorders Market Overview

The global respiratory disorders market reached US$ 121.06 billion in 2024, up from US$ 114.11 billion in 2023, and is projected to grow to US$ 213.12 billion by 2033, registering a CAGR of 6.6% during 2025-2033. The market's steady growth is driven by increasing incidences of chronic respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD), alongside infectious respiratory diseases. Rising urban air pollution, high smoking prevalence, and an ageing global population further exacerbate respiratory health challenges, driving demand for effective treatment and management solutions.

Therapeutic advancements, including biologics and advanced inhalation therapies, are significantly shaping market growth. Leading products such as Trelegy Ellipta and Breo Ellipta (GSK), Spiriva Respimat (Boehringer Ingelheim), Symbicort (AstraZeneca), Dupixent (Sanofi/Regeneron), and Ohtuvayre (Merck/Verona Pharma) are driving adoption of innovative treatment regimens. In parallel, the device segment is expanding due to home-based and connected respiratory management systems, exemplified by ResMed's AirSense 11 CPAP, Philips' DreamStation 2, and Fisher & Paykel's Optiflow systems, supporting patient adherence and remote monitoring.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/respiratory-disorders-market?Juli

Recent Developments:

✅ December 2025: A leading pharmaceutical company launched an extended‐release inhalation therapy with improved dosing convenience and reduced side effects, designed to enhance long‐term asthma and COPD management.

✅ October 2025: A major medtech firm introduced an AI‐integrated connected inhaler platform that tracks patient usage patterns and syncs with mobile health apps to improve adherence and offer personalized feedback.

✅ August 2025: ResMed expanded its AirSense 11 series with integrated remote monitoring features for clinicians, enabling more responsive care for sleep apnea and related respiratory disorders.

✅ June 2025: A global health technology provider rolled out a next‐generation portable oxygen concentrator with extended battery life and enhanced portability, supporting increased home‐based respiratory care.

✅ March 2025: A biotech company announced positive Phase III results for a novel biologic targeting severe eosinophilic asthma, showing significant reduction in exacerbations and improved lung function compared to standard therapy.

Mergers & Acquisitions:

✅ November 2025: A leading global pharmaceutical company completed the acquisition of a biotech firm specializing in severe asthma biologics, expanding its respiratory portfolio and boosting late‐stage pipeline assets.

✅ September 2025: A major medical device manufacturer acquired a connected inhaler and digital adherence platform developer to strengthen its smart respiratory care offerings and remote patient monitoring capabilities.

✅ July 2025: A top respiratory equipment provider merged with a portable oxygen and ventilation systems specialist, enhancing its capabilities in home‐based respiratory support solutions.

✅ May 2025: A multinational healthcare group acquired a novel COPD therapy developer focused on next‐generation inhalation formulations to broaden its chronic respiratory disease treatment pipeline.

✅ February 2025: A large diagnostics and medical technologies company completed the acquisition of a respiratory diagnostics startup with advanced spirometry and lung function testing technologies for integrated clinical use.

Key Players:

• GSK - Holds approximately 16.8% market share, driven by its flagship respiratory products like Trelegy Ellipta and Breo Ellipta, as well as innovations in connected inhalers and digital adherence programs.

• AstraZeneca - Holds around 14.5% share, supported by Symbicort, Fasenra, and other asthma and COPD therapies, along with strong R&D pipelines in biologics.

• Boehringer Ingelheim - Accounts for 12.7% of the market, fueled by Spiriva Respimat and its home-respiratory device solutions.

• Sanofi - Holds roughly 11.2% share, strengthened by Dupixent and other biologics targeting severe asthma and eosinophilic conditions.

• Regeneron - Holds 6.8% share, primarily through its collaboration with Sanofi for Dupixent and other pipeline biologics.

• Novartis - Accounts for 7.4% market share, with a portfolio including inhaled therapies and specialty respiratory biologics.

• Merck & Co. - Holds about 6.0% share, driven by innovative respiratory medications and ongoing clinical development in COPD and asthma.

• Pfizer - Holds 5.5% share, supported by partnerships and respiratory treatment formulations for chronic pulmonary diseases.

• Teva Pharmaceutical Industries - Accounts for 6.1%, with its generic inhalers and respiratory devices contributing to a strong presence in multiple regions.

• F. Hoffmann-La Roche - Holds 4.0%, leveraging its diagnostics and device technologies to complement respiratory treatment solutions.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=respiratory-disorders-market?Juli

Market Segmentation:

➥By Disease Type, Chronic Obstructive Pulmonary Disease (COPD) dominates the respiratory disorders market, accounting for approximately 32% of the global share in 2024. COPD's prevalence, especially among older adults and smokers, has driven strong demand for both therapeutics and devices. Asthma follows closely with a 28% share, supported by increasing urban pollution, allergic triggers, and adoption of biologics and inhaler therapies. Pneumonia accounts for around 12%, driven by hospitalizations, vaccination programs, and rising infections in developing countries. Cystic Fibrosis and Interstitial Lung Disease / Idiopathic Pulmonary Fibrosis (ILD/IPF) collectively hold 8%, reflecting rare disease status but high treatment cost and specialized care. Tuberculosis contributes 7%, primarily in Asia-Pacific and Africa, where prevalence remains significant. The remaining 13% is comprised of other respiratory conditions including bronchiectasis and pulmonary hypertension.

➥By Treatment Type, therapeutics account for the majority of the market at 68%, fueled by prescription drugs, biologics, and combination inhalers for chronic respiratory diseases. Devices represent 32%, driven by innovations in home respiratory care, such as CPAP, BiPAP, connected inhalers, oxygen concentrators, and monitoring systems, which are increasingly used for remote patient management and telehealth programs.

➥By End-User, hospitals dominate with a 45% share, serving acute cases, severe chronic conditions, and inpatient care for respiratory disorders. Specialty clinics, including pulmonology and asthma centers, hold around 30%, reflecting outpatient management and regular follow-ups. Home care settings account for 25%, supported by rising adoption of portable inhalers, oxygen therapy devices, telemonitoring solutions, and home-based treatment programs, particularly in developed regions such as North America and Europe.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/respiratory-disorders-market?Juli

Market Dynamics:

Drivers:
The growth of the global respiratory disorders market is being significantly driven by the introduction of FDA-approved therapeutics, which provide new mechanisms of action, expand patient access, and deliver higher-value treatment options in previously stagnant disease categories. For instance, in May 2025, GSK plc announced FDA approval for Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilic phenotype. Similarly, in March 2025, Celltrion received FDA approval for OMLYCLO (omalizumab-igec), the first interchangeable biosimilar to XOLAIR (omalizumab), for treating moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), IgE-mediated food allergies, and chronic spontaneous urticaria (CSU).

Beyond therapeutics, approvals of novel vaccines complement overall treatment strategies. However, therapeutic approvals have a powerful impact on market expansion as they increase average revenue per patient, extend treatment duration, and drive reimbursement coverage. Each new FDA-approved therapeutic redefines the standard of care, attracts investment from payers and providers, and displaces older therapies, thereby stimulating innovation and growth in the respiratory disorders market.

Restraints:
Conversely, heavy competition and generic pressure are increasingly constraining market growth by eroding profit margins, triggering price wars, and reducing long-term investment incentives in established therapeutic classes. High-value inhaled therapies such as Advair (fluticasone/salmeterol) and Flovent (fluticasone), which historically dominated asthma and COPD treatment, have experienced steep revenue declines following patent expiries and the introduction of multiple generics in the U.S. and Europe. For example, Mylan's launch of generic Advair Diskus led to price reductions exceeding 60%, forcing original manufacturers to pivot toward next-generation combination inhalers like Trelegy Ellipta to offset losses.

Regional Insights:

North America dominates the respiratory disorders market with an estimated 35% share (USD 42.37 billion in 2024). The region's leadership is driven by advanced healthcare infrastructure, high adoption of biologics and inhalation devices, and strong government initiatives supporting respiratory health. The U.S. leads the region due to widespread use of FDA-approved therapies such as Trelegy Ellipta, Spiriva Respimat, and Nucala, alongside advanced home-based respiratory monitoring solutions like ResMed's AirSense 11 CPAP.

Europe holds approximately 25% share (USD 30.27 billion in 2024), supported by established healthcare systems, robust reimbursement policies, and early adoption of innovative respiratory therapies. Countries such as Germany, France, and the UK are investing heavily in hospital infrastructure, smart inhalers, and biologics for asthma and COPD, which are accelerating market growth in the region.

Asia-Pacific is the fastest-growing market, accounting for 28% share (USD 33.89 billion in 2024), with a projected CAGR of over 8% during 2025-2033. Rapid urbanization, increasing air pollution, and rising smoking prevalence in countries like China and India are driving demand for advanced respiratory treatments. The growth is further supported by increasing healthcare spending, awareness programs for COPD and asthma, and expanding access to inhalers and biologics.

Latin America, Middle East & Africa (LAMEA) contribute the remaining 12% share (USD 14.51 billion in 2024). Growth in these regions is fueled by improving healthcare infrastructure, rising prevalence of chronic respiratory diseases, and greater access to therapeutics and devices in urban centers. Key markets include Brazil, Mexico, South Africa, and the UAE, where awareness campaigns and increasing insurance coverage are gradually expanding market adoption.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.